- Home
- SKYA vs LTRN Comparison
SKYA vs LTRN Comparison
Compare SKYA & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYA | LTRN |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.0M | 46.8M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SKYA | LTRN |
|---|---|---|
| Price | $0.99 | $2.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 157.9K | 71.3K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $204,120.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $1.11 |
| 52 Week High | $1.54 | $4.70 |
Technical Indicators
Market Signals| Indicator | SKYA | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 35.01 | 37.21 |
| Support Level | $0.91 | $2.49 |
| Resistance Level | $1.26 | $3.01 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 2.94 | 40.35 |
Price Performance
Historical ComparisonAbout SKYA SkyAI Inc. Common Stock
SkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company's platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.